Full Press Release Details
Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on
August 4th in New York
VICTORIA, British Columbia--(BUSINESS WIRE)--July 28, 2016--Aurinia
Pharmaceuticals Inc. (NASDAQ:AUPH;TSX:AUP) today announced it will host
a Lupus Nephritis expert breakfast on Thursday, August 4th from 8:00am
to 9:30am EDT in New York.
The topics of the presentations will include current treatments for
Lupus Nephritis, its disease burden, as well as pharmacoeconomic and
pricing dynamics for new products for less common diseases in the US
market place. The company will also take this opportunity to review in
further detail the most recent proof of concept AURION study data, and
the Phase IIb AURA-LV study design.
| The meeting will feature the following speakers: | |
| Dr. Amit Saxena, Assistant Professor at the Department of Medicine at NYU Langone Medical Center. | |
| Dr. Doug Paul, PharmD, PhD and Adjunct Assistant Professor at the University of Mississippi School of Pharmacy. | |
| Mr. Robert Huizinga, VP of Clinical Affairs,Aurinia Pharmaceuticals. | |
| Mr. Charles Rowland, CEO, Aurinia Pharmaceuticals. |
The event is intended for investors, sell-side analysts, and business
development professionals. If you would like to attend in person, please
contact Mac MacDonald at 212-915-2567 or via e-mail at Mac@LifeSciAdvisors.com
A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20160804/reg.jsp
and the Investors section of the Company's website at http://www.auriniapharma.com/dnn/ForInvestors/Webcasts.aspx.
Aurinia is a clinical stage pharmaceutical company focused on the global
nephrology market. The fully-enrolled Phase 2b AURA-LV clinical trial is
evaluating the efficacy of its lead drug, voclosporin, as a treatment
for active LN. LN is an inflammation of the kidneys, that if
inadequately treated can lead to end-stage renal disease, making LN a
serious and potentially life-threatening condition.
Voclosporin is a novel and potentially best-in-class calcineurin
inhibitor ("CNI") with extensive clinical data in over 2,000 patients in
other indications. Voclosporin is made by a modification of a single
amino acid of the cyclosporine molecule (a CNI approved for use in
transplant patients since 1983). This modification results in a more
predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency vs. cyclosporine, an altered metabolic profile, and
potential for flat dosing.
Voclosporin is a novel and potentially best-in-class calcineurin
inhibitor ("CNI") with extensive clinical data in over 2,000 patients in
other indications. Voclosporin is made by a modification of a single
amino acid of the cyclosporine molecule (a CNI approved for use in
transplant patients since 1983). This modification results in a more
predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency vs. cyclosporine, an altered metabolic profile, and
potential for flat dosing.
The AURA-LV study or "Aurinia Urine Protein Reduction in Active Lupus
Nephritis Study" is an adequate and well-controlled clinical trial that
enrolled 265 patients and is being conducted in over 20 countries
worldwide. This trial will compare the efficacy of voclosporin against
placebo in achieving remission in patients with active lupus nephritis.
The AURA-LV study is designed to demonstrate that voclosporin can induce
a rapid and sustained reduction of proteinuria in the presence of
extremely low steroid exposure. It will compare two dosage groups of
voclosporin (23.7mg and 39.5mg) compared to placebo, with all patients
receiving mycophenolate mofetil (MMF) and oral corticosteroids as
background therapy. There will be a primary analysis to determine
complete remission at week 24 (confirmed at 26 weeks) and various
secondary analyses at week 48 which include biomarkers and markers of
The AURION study or "Aurinia Early Urinary Protein Reduction Predicts
Response Study" is an open label, exploratory study being conducted in
multiple sites in Malaysia to assess the short term predictors of
response using voclosporin (23.7mg) in combination with mycophenolate
mofetil and oral corticosteroids in patients with active lupus
nephritis. This study will examine biomarkers of disease activity at 8
weeks and their ability to predict response at 24 and 48 weeks.
We seek Safe Harbor.
Aurinia Pharmaceuticals Inc.
Associate Vice-President Communications & Advocacy
Financial Communications Inc.
Barry Mire,416-644-2020